Bioxytran, Inc., a clinical-stage biotechnology company, has announced a research collaboration with the University of Georgia (UGA) to explore the efficacy of its lead drug candidate in blocking the Highly Pathogenic Avian Influenza (HPAI) H5N1 virus, commonly known as bird flu.
The collaboration is part of a $100 million grant aimed at evaluating Bioxytran’s novel galectin antagonist as a potential therapeutic for infected poultry. The research, led by Dr. Daniela Rajao from UGA's College of Veterinary Medicine, aims to address the urgent threat H5N1 poses to the global food supply and economy.
Bioxytran’s drug candidate, PHM23, utilizes a novel mechanism that targets galectin proteins critical to viral replication. By blocking viral spike proteins from attaching to host cells, the therapy seeks to neutralize the virus and halt its spread. Preliminary in vitro studies have shown the molecule's effectiveness against viruses similar to H5N1.
The partnership has already garnered significant academic recognition, with UGA selecting PHM23 as a featured molecule in its grant submission to the U.S. Department of Agriculture’s $100 million HPAI Poultry Innovation Grand Challenge. This inclusion highlights the scientific promise of Bioxytran’s platform in addressing major agricultural challenges.
Current protocols for managing bird flu outbreaks often require the culling of entire flocks to prevent the virus's spread, resulting in significant economic losses. Bioxytran’s approach could offer a more effective and humane alternative, enabling rapid containment of the virus and mitigating its economic impact.
Bioxytran is actively seeking further partnerships with academic, industry, and government stakeholders to accelerate the development and deployment of PHM23. The company aims to provide a sustainable solution to protect animal health and stabilize the food supply chain.
Forward-looking statements in the announcement emphasize the potential risks and uncertainties associated with the development and performance of the technology. Bioxytran underscores its commitment to updating stakeholders as required under federal securities laws.